




Instance: composition-en-168192a0c6d5270d5bcdb3cfa6cdd926
InstanceOf: CompositionUvEpi
Title: "Composition for mimpara Package Leaflet"
Description:  "Composition for mimpara Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/04/292/001 – 30 mg carton with 14 tablets"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp168192a0c6d5270d5bcdb3cfa6cdd926)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - mimpara"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Mimpara is and what it is used for </li>
<li>What you need to know before you take Mimpara </li>
<li>How to take Mimpara </li>
<li>Possible side effects </li>
<li>How to store Mimpara </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What mimpara is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What mimpara is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mimpara works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in 
your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four 
small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).  </p>
<p>Mimpara is used in adults:<br />
<em> to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis 
to clear their blood of waste products. 
* to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid 
cancer.<br />
</em> to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary 
hyperparathyroidism when removal of the gland is not possible. </p>
<p>Mimpara is used in children aged 3 years to less than 18 years of age:<br />
* to treat secondary hyperparathyroidism in patients with serious kidney disease who need 
dialysis to clear their blood of waste products, whose condition is not controlled with other 
treatments. </p>
<p>In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands. 
 Primary  means that the hyperparathyroidism is not caused by any other condition and  secondary<br />
means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Both primary 
and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone 
pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take mimpara"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take mimpara"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Mimpara if you are allergic to cinacalcet or any of the other ingredients of this medicine 
(listed in section 6).  </p>
<p>Do not take Mimpara if you have low levels of calcium in your blood. Your doctor will monitor your 
blood calcium levels. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before taking Mimpara. </p>
<p>Before you start taking Mimpara, tell your doctor if you have or have ever had: 
* seizures (fits or convulsions). The risk of having seizures is higher if you have had them before;<br />
* liver problems; 
* heart failure.  </p>
<p>Mimpara reduces calcium levels. Life threatening events and fatal outcomes associated with low 
calcium levels (hypocalcaemia) have been reported in adults and children treated with Mimpara.  </p>
<p>Please tell your doctor if you experience any of the following which may be signs of low calcium 
levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or 
around your mouth or seizures, confusion or loss of consciousness while being treated with Mimpara.  </p>
<p>Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an 
unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines 
known to cause heart rhythm problems, while taking Mimpara.  </p>
<p>For additional information see section 4. During treatment with Mimpara, tell your doctor: 
* if you start or stop smoking, as this may affect the way Mimpara works. </p>
<p>Children and adolescents 
Children under the age of 18 with parathyroid cancer or primary hyperparathyroidism must not take 
Mimpara. </p>
<p>If you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium 
levels before starting treatment with Mimpara and during treatment with Mimpara. You should inform 
your doctor if you experience any of the signs of low calcium levels as described above.   </p>
<p>It is important that you take your dose of Mimpara as advised by your doctor.  </p>
<p>Other medicines and Mimpara 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines 
particularly etelcalcetide or any other medicines that lower the level of calcium in your blood. </p>
<p>You should not receive Mimpara together with etelcalcetide. </p>
<p>Tell your doctor if you are taking the following medicines  </p>
<p>Medicines such as these can affect how Mimpara works: 
* medicines used to treat skin and fungal infections (ketoconazole, itraconazole and 
voriconazole); 
* medicines used to treat bacterial infections (telithromycin, rifampicin and ciprofloxacin); 
* a medicine used to treat HIV infection and AIDS (ritonavir); 
* a medicine used to treat depression (fluvoxamine). </p>
<p>Mimpara may affect how medicines such as the following work: 
* medicines used to treat depression (amitriptyline, desipramine, nortriptyline and 
clomipramine); 
* a medicine used to relieve cough (dextromethorphan); 
* medicines used to treat changes in heart rate (flecainide and propafenone);<br />
* a medicine used to treat high blood pressure (metoprolol). </p>
<p>Mimpara with food and drink 
Mimpara should be taken with or shortly after food. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Mimpara has not been tested in pregnant women. In case of pregnancy, your doctor may decide to 
modify your treatment, as Mimpara might harm the unborn baby.  </p>
<p>It is not known whether Mimpara is excreted in human milk. Your doctor will discuss with you if you 
should discontinue either breast-feeding or treatment with Mimpara.  </p>
<p>Driving and using machines 
Dizziness and seizures have been reported by patients taking Mimpara. If you experience these side 
effects, do not drive or operate machines. </p>
<p>Mimpara contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicinal product. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take mimpara"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take mimpara"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are unsure. Your doctor will tell you how much Mimpara you must take. </p>
<p>Mimpara must be taken orally, with or shortly after food. The tablets must be taken whole and are not 
to be chewed, crushed or divided. </p>
<p>Mimpara is also available as granules in capsules for opening. Children who require doses lower than 
30 mg, or who are unable to swallow tablets should receive Mimpara granules. </p>
<p>Your doctor will take regular blood samples during treatment to monitor your progress and will adjust 
your dose if necessary. </p>
<p>If you are being treated for secondary hyperparathyroidism 
The usual starting dose for Mimpara in adults is 30 mg (one tablet) once per day. </p>
<p>The usual starting dose of Mimpara for children aged 3 years to less than 18 years of age is no more 
than 0.20 mg/kg of body weight daily. </p>
<p>If you are being treated for parathyroid cancer or primary hyperparathyroidism 
The usual starting dose for Mimpara in adults is 30 mg (one tablet) twice per day.  </p>
<p>If you take more Mimpara than you should 
If you take more Mimpara than you should you must contact your doctor immediately. Possible signs 
of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures. </p>
<p>If you forget to take Mimpara 
Do not take a double dose to make up for a forgotten dose.  </p>
<p>If you have forgotten a dose of Mimpara, you should take your next dose as normal. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Please tell your doctor immediately:   </p>
<ul>
<li>If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. 
These may be signs that your calcium levels are too low (hypocalcaemia). </li>
<li>If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty 
in swallowing or breathing (angioedema). </li>
</ul>
<p>Very common: may affect more than 1 in 10 people<br />
* nausea and vomiting, these side effects are normally quite mild and do not last for long.  </p>
<p>Common: may affect up to 1 in 10 people 
* dizziness 
* numbness or tingling sensation (paraesthesia) 
* loss (anorexia) or decrease of appetite<br />
<em> muscle pain (myalgia) 
* weakness (asthenia) 
* rash 
* reduced testosterone levels 
* high potassium levels in the blood (hyperkalaemia)<br />
</em> allergic reactions (hypersensitivity) 
* headache 
* seizures (convulsions or fits) 
* low blood pressure (hypotension) 
* upper respiratory infection 
* breathing difficulties (dyspnoea)<br />
* cough 
* indigestion (dyspepsia) 
* diarrhoea 
* abdominal pain, abdominal pain   upper 
* constipation 
* muscle spasms 
* back pain 
* low calcium levels in the blood (hypocalcaemia). </p>
<p>Not known: frequency cannot be estimated from available data 
* Hives (urticaria) 
* Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or 
breathing (angioedema) 
* Unusually fast or pounding heart beat which may be associated with low levels of calcium in 
your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia). </p>
<p>After taking Mimpara a very small number of patients with heart failure had worsening of their 
condition and/or low blood pressure (hypotension). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store mimpara"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store mimpara"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. 
Do not use this medicine after the expiry date which is stated on the carton and bottle. The expiry date 
refers to the last day of that month. </p>
<p>This medicinal product does not require any special storage conditions. 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Mimpara contains 
- The active substance is cinacalcet. Each film-coated tablet contains 30 mg, 60 mg or 90 mg of 
cinacalcet (as hydrochloride).<br />
- The other ingredients are: 
* Pre-gelatinised maize starch 
* Microcrystalline cellulose 
* Povidone 
* Crospovidone 
* Magnesium stearate 
* Colloidal anhydrous silica  </p>
<ul>
<li>The tablets are coated with: </li>
<li>Carnauba wax </li>
<li>Opadry green (containing lactose monohydrate, hypromellose, titanium dioxide (E171), 
glycerol triacetate, FD&amp;C Blue (E132), iron oxide yellow (E172)) </li>
<li>Opadry clear (containing hypromellose, macrogol) </li>
</ul>
<p>What Mimpara looks like and contents of the pack 
Mimpara is a light green film-coated tablet. They are oval-shaped and have  30 ,  60  or  90  marked 
on one side and  AMG  on the other side.  </p>
<p>30 mg tablets are approximately 9.7 mm long and 6.0 mm wide. 
60 mg tablets are approximately 12.2 mm long and 7.6 mm wide. 
90 mg tablets are approximately 13.9 mm long and 8.7 mm wide. </p>
<p>Mimpara is available in blisters of 30 mg, 60 mg or 90 mg film-coated tablets. Each blister pack 
contains either 14, 28 or 84 tablets in a carton. 
Mimpara is available in bottles of 30 mg, 60 mg or 90 mg film-coated tablets, inside a carton. Each 
bottle holds 30 tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
The Netherlands </p>
<p>Marketing Authorisation Holder 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
The Netherlands </p>
<p>Manufacturer 
Amgen NV 
Telecomlaan 5-7 
1831 Diegem 
Belgium  </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien 
s.a. Amgen n.v. 
Tel/T l: +32 (0)2 7752Lietuva 
Amgen Switzerland AG Vilniaus filialas 
Tel: +370 5 219 7  </p>
<p>.: +359 (0)2 424 7Luxembourg/Luxemburg 
s.a. Amgen<br />
Belgique/Belgien 
Tel/T l: +32 (0)2 7752 esk  republika 
Amgen s.r.o. 
Tel: +420 221 773 Magyarorsz g 
Amgen Kft. 
Tel.: +36 1 35 44 Danmark 
Amgen, filial af Amgen AB, Sverige 
Tlf: +45 39617Malta 
Amgen B.V. 
The Netherlands 
Tel: +31 (0)76 5732Deutschland 
AMGEN GmbH 
Tel.: +49 89 1490Nederland 
Amgen B.V. 
Tel: +31 (0)76 5732Eesti 
Amgen Switzerland AG Vilniaus filialas 
Tel: +372 586 09Norge 
Amgen AB 
Tel: +47 23308<br />
Amgen      . . .<br />
 .: +30 210 3447 sterreich 
Amgen GmbH<br />
Tel: +43 (0)1 50 Espa a 
Amgen S.A. 
Tel: +34 93 600 18 Polska 
Amgen Biotechnologia Sp. z o.o. 
Tel.: +48 22 581 3France 
Amgen S.A.S. 
T l: +33 (0)9 69 363 Portugal 
Amgen Biofarmac utica, Lda. 
Tel: +351 21 4220Hrvatska 
Amgen d.o.o. 
Tel: +385 (0)1 562 57 Rom nia 
Amgen Rom nia SRL 
Tel: +4021 527 3Ireland 
Amgen Ireland Limited 
Tel: +353 1 8527Slovenija 
AMGEN zdravila d.o.o. 
Tel: +386 (0)1 585 1 sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Amgen Slovakia s.r.o. 
Tel: +421 2 321 114 Italia 
Amgen S.r.l. 
Tel: +39 02 6241Suomi/Finland 
Amgen AB, sivuliike Suomessa/Amgen AB, filial 
i Finland 
Puh/Tel: +358 (0)9 54900K<br />
C.A. Papaellinas Ltd 
 .: +357 22741 Sverige 
Amgen AB<br />
Tel: +46 (0)8 6951Latvija 
Amgen Switzerland AG R gas fili le 
Tel: +371 257 25United Kingdom (Northern Ireland) 
Amgen Limited 
Tel: +44 (0)1223 420This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-168192a0c6d5270d5bcdb3cfa6cdd926
InstanceOf: CompositionUvEpi
Title: "Composition for mimpara Package Leaflet"
Description:  "Composition for mimpara Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/04/292/001 – 30 mg carton with 14 tablets"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp168192a0c6d5270d5bcdb3cfa6cdd926)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - mimpara"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Mimpara 
3. Sådan skal De tage Mimpara 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What mimpara is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What mimpara is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mimpara virker ved at kontrollere niveauerne af paratyroideahormon (PTH), calcium og fosfor i 
kroppen. Det bruges til behandling af sygdomme, der skyldes problemer med organer kaldet 
biskjoldbruskkirtlerne. Biskjoldbruskkirtlerne er fire små kirtler i halsen, tæt ved skjoldbruskkirtlen, 
som producerer paratyroideahormon (PTH). </p>
<p>Mimpara bruges til voksne til: </p>
<ul>
<li>
<p>at behandle sekundær hyperparatyroidisme hos voksne med alvorlig nyresygdom, som har 
behov for dialyse for at fjerne affaldsprodukter fra blodet. </p>
</li>
<li>
<p>at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos voksne patienter med 
biskjoldbruskkirtelkræft. </p>
</li>
<li>
<p>at reducere forhøjede calciumniveauer i blodet (hyperkalcæmi) hos voksne patienter med 
primær hyperparatyroidisme, hvor det ikke er muligt at fjerne biskjoldbruskkirtlen. </p>
</li>
</ul>
<p>Mimpara bruges til børn fra 3 år og op til 18 år til: </p>
<ul>
<li>at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, som har 
behov for dialyse for at fjerne affaldsprodukter fra blodet, og hvis sygdom ikke kan kontrolleres 
med andre behandlinger. </li>
</ul>
<p>Ved primær og sekundær hyperparatyroidisme afgiver biskjoldbruskkirtlerne for meget PTH. 
“Primær" betyder, at hyperparatyroidismen ikke skyldes nogen anden tilstand, og “sekundær" betyder, 
at hyperparatyroidismen skyldes en anden tilstand, for eksempel nyresygdom. Både primær og 
sekundær hyperparatyroidisme kan medføre et for lavt calciumniveau i knoglerne, som kan give 
smerter i knoglerne, knoglebrud, hjerte-kar-sygdom, nyresten, psykiske lidelser og koma. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take mimpara"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take mimpara"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Mimpara, hvis De er allergisk over for cinacalcet eller et af de øvrige indholdsstoffer 
(angivet i punkt 6). </p>
<p>Tag ikke Mimpara, hvis De har lave calciumniveauer i blodet. Deres læge vil kontrollere Deres 
calciumniveauer i blodet. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før De tager Mimpara. </p>
<p>Tal med Deres læge, før De begynder at tage Mimpara, hvis De lider eller nogen sinde har lidt af: </p>
<ul>
<li>
<p>krampeanfald (anfald eller kramper). Risikoen for at få krampeanfald er større, hvis De 
tidligere har haft krampeanfald, </p>
</li>
<li>
<p>leversygdom, </p>
</li>
<li>
<p>hjertesvigt. </p>
</li>
</ul>
<p>Mimpara nedsætter calciumniveauerne. Der er indberettet livstruende hændelser og dødeligt udfald i 
forbindelse med lave calciumniveauer (hypokalcæmi) hos voksne og børn, der blev behandlet med 
Mimpara. </p>
<p>Fortæl det til Deres læge, hvis De oplever en eller flere af disse tilstande, som kan være tegn på lave 
calciumniveauer: spasmer, muskelspjæt eller muskelkramper, følelsesløshed eller prikken i fingre, 
tæer eller omkring munden, kramper, forvirring eller bevidstløshed, mens De er i behandling med 
Mimpara. </p>
<p>Lave calciumniveauer kan påvirke Deres hjerterytme. Fortæl det til Deres læge, hvis De får unormalt 
hurtige eller bankende hjerteslag, hvis De får hjerterytmeproblemer, eller hvis De tager medicin, der 
vides at forårsage hjerterytmeproblemer, mens De tager Mimpara. </p>
<p>Punkt 4 nedenfor indeholder mere information. </p>
<p>Tal med deres læge undervejs i behandlingen med Mimpara: </p>
<ul>
<li>hvis De begynder eller holder op med at ryge, da det kan ændre virkningen af Mimpara. </li>
</ul>
<p>Børn og unge 
Børn og unge under 18 år med biskjoldbruskkirtelkræft eller primær hyperparatyroidisme må ikke få 
Mimpara. </p>
<p>Hvis De behandles for sekundær hyperparatyroidisme, skal Deres læge kontrollere Deres 
calciumniveauer, inden behandlingen med Mimpara starter og under behandlingen med Mimpara. De 
skal fortælle det til Deres læge, hvis De får et eller flere af de tegn på lave calciumniveauer, der 
beskrives ovenfor. </p>
<p>Det er vigtigt, at De tager deres Mimpara-dosis efter lægens anvisninger. </p>
<p>Brug af anden medicin sammen med Mimpara 
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin. Det gælder især etelcalcetid eller anden 
medicin, der sænker niveauet af calcium i blodet. </p>
<p>De må ikke få Mimpara samtidig med etelcalcetid. </p>
<p>Fortæl det til Deres læge, hvis De tager en eller flere af følgende lægemidler. </p>
<p>Nedenstående medicin kan have betydning for, hvordan Mimpara virker: </p>
<ul>
<li>
<p>medicin, som anvendes til behandling af hud- og svampeinfektioner (ketoconazol, itraconazol 
og voriconazol), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af bakterieinfektioner (telithromycin, rifampicin og 
ciprofloxacin), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af hiv og AIDS (ritonavir), </p>
</li>
<li>
<p>medicin, der anvendes til behandling af depression (fluvoxamin). </p>
</li>
</ul>
<p>Mimpara kan have betydning for, hvordan følgende medicin virker: </p>
<ul>
<li>
<p>medicin, som anvendes til behandling af depression (amitriptylin, desipramin, nortriptylin og 
clomipramin), </p>
</li>
<li>
<p>medicin, som anvendes til at lindre hoste (dextromethorphan), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af hjerterytmeforstyrrelser (flecainid og propafenon), </p>
</li>
<li>
<p>medicin, som anvendes til behandling af forhøjet blodtryk (metoprolol). </p>
</li>
</ul>
<p>Brug af Mimpara sammen med mad og drikke 
Mimpara skal tages sammen med eller kort tid efter indtagelse af mad. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Mimpara er ikke blevet undersøgt på gravide kvinder. Hvis De er gravid, kan lægen beslutte at ændre 
behandlingen, da Mimpara kan være skadeligt for fostret. </p>
<p>Det vides ikke, om Mimpara udskilles i mælken hos mennesker. De og Deres læge skal afklare, om det 
er bedst at ophøre med amning eller afbryde behandlingen med Mimpara. </p>
<p>Trafik- og arbejdssikkerhed 
Der er indberettet svimmelhed og krampeanfald fra patienter, som fik Mimpara. Hvis De oplever disse 
bivirkninger, må De ikke køre bil eller betjene maskiner. </p>
<p>Mimpara indeholder lactose 
Kontakt lægen, før De tager denne medicin, hvis lægen har fortalt Dem, at De ikke tåler visse 
sukkerarter. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take mimpara"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take mimpara"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er De i tvivl, så spørg 
lægen eller apotekspersonalet. Deres læge vil fortælle Dem, hvor meget Mimpara De skal tage. </p>
<p>Mimpara skal indtages gennem munden sammen med eller kort tid efter indtagelse af mad. Tabletterne 
skal tages hele og må ikke tygges, knuses eller deles. </p>
<p>Mimpara fås også som granulat i kapsler, der skal åbnes. Børn, der har brug for doser under 30 mg, 
eller som ikke kan synke tabletterne, skal have Mimpara granulat. </p>
<p>Deres læge vil tage regelmæssige blodprøver under behandlingen for at følge udviklingen og justere 
dosis efter behov. </p>
<p>Hvis De er under behandling for sekundær hyperparatyroidisme 
Den normale startdosis af Mimpara for voksne er 30 mg (én tablet) én gang dagligt. </p>
<p>Den normale startdosis af Mimpara for børn i alderen 3 år og op til 18 år er maksimalt 0,20 mg/kg 
legemsvægt dagligt. </p>
<p>Hvis De er under behandling for biskjoldbruskkirtelkræft eller primær hyperparatyroidisme 
Den normale startdosis af Mimpara for voksne er 30 mg (én tablet) to gange dagligt. </p>
<p>Hvis De har taget for meget Mimpara 
Hvis De har taget for meget Mimpara, skal De straks kontakte Deres læge. Tegn på en overdosis kan 
omfatte følelsesløshed eller en prikken omkring munden, muskelsmerter eller -kramper samt 
krampeanfald. </p>
<p>Hvis De har glemt at tage Mimpara 
De må ikke tage en dobbeltdosis som erstatning for den glemte tablet. </p>
<p>Hvis De har glemt at tage en dosis Mimpara, skal De tage den næste dosis som normalt. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, De er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det straks til lægen: </p>
<ul>
<li>
<p>hvis De begynder at få følelsesløshed eller en prikken omkring munden, muskelsmerter eller -
kramper eller krampeanfald. Dette kan være tegn på, at Deres calciumniveauer er for lave 
(hypokalcæmi). </p>
</li>
<li>
<p>hvis De får hævelse i ansigt, læber, mund, tunge eller hals, som kan give synke- eller 
åndedrætsbesvær (angioødem). </p>
</li>
</ul>
<p>Meget almindelige: kan ramme mere end 1 ud af 10 personer </p>
<ul>
<li>kvalme og opkastning. Disse bivirkninger er normalt ret milde og er ikke vedvarende. </li>
</ul>
<p>Almindelige: kan ramme op til 1 ud af 10 personer </p>
<ul>
<li>
<p>svimmelhed, </p>
</li>
<li>
<p>følelsesløshed eller prikkende fornemmelse (paræstesi), </p>
</li>
<li>
<p>appetitløshed eller nedsat appetit, </p>
</li>
<li>
<p>muskelsmerter (myalgi), </p>
</li>
<li>
<p>udmattethed (asteni), </p>
</li>
<li>
<p>udslæt, </p>
</li>
<li>
<p>reducerede testosteronniveauer, </p>
</li>
<li>
<p>høje kaliumniveauer i blodet (hyperkaliæmi), </p>
</li>
<li>
<p>allergiske reaktioner (overfølsomhed), </p>
</li>
<li>
<p>hovedpine, </p>
</li>
<li>
<p>kramper eller krampeanfald, </p>
</li>
<li>
<p>lavt blodtryk, </p>
</li>
<li>
<p>infektion i øvre luftveje, </p>
</li>
<li>
<p>vejrtrækningsbesvær (dyspnø), </p>
</li>
<li>
<p>hoste, </p>
</li>
<li>
<p>fordøjelsesbesvær (dyspepsi), </p>
</li>
<li>
<p>diarré, </p>
</li>
<li>
<p>mavesmerter - smerter i den øvre del af maven, </p>
</li>
<li>
<p>forstoppelse, </p>
</li>
<li>
<p>muskelspasmer, </p>
</li>
<li>
<p>rygsmerter, </p>
</li>
<li>
<p>lave calciumniveauer i blodet (hypokalcæmi). </p>
</li>
</ul>
<p>Ikke kendt: hyppigheden kan ikke vurderes ud fra tilgængelige data </p>
<ul>
<li>
<p>nældefeber (urticaria), </p>
</li>
<li>
<p>hævelse i ansigt, læber, mund, tunge eller hals, som kan give synke- eller åndedrætsbesvær 
(angioødem), </p>
</li>
<li>
<p>unormalt hurtige eller bankende hjerteslag, der kan være forbundet med lave niveauer af 
calcium i Deres blod (QT-forlængelse og ventrikulær arytmi sekundært til hypokalcæmi). </p>
</li>
</ul>
<p>I meget få tilfælde hos patienter med hjertesvigt blev dette forværret efter indtagelse af Mimpara, 
og/eller patienterne fik lavt blodtryk (hypotension). </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, apotekspersonalet eller sygeplejersken. 
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store mimpara"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store mimpara"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og blisterkortet efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. 
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og beholderen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaring. 
Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.  </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mimpara indeholder:</p>
<ul>
<li>Aktivt stof: cinacalcet. Hver filmovertrukket tablet indeholder 30 mg, 60 mg eller 90 mg 
cinacalcet (som hydrochlorid). </li>
<li>
<p>Øvrige indholdsstoffer: </p>
</li>
<li>
<p>Pregelatineret majsstivelse, </p>
</li>
<li>
<p>Mikrokrystallinsk cellulose, </p>
</li>
<li>
<p>Povidon, </p>
</li>
<li>
<p>Crospovidon, </p>
</li>
<li>
<p>Magnesiumstearat, </p>
</li>
<li>
<p>Kolloid vandfri silica. </p>
</li>
<li>
<p>Tabletterne er overtrukket med: </p>
</li>
<li>
<p>Carnaubavoks, </p>
</li>
<li>
<p>Opadry grøn (indeholder lactosemonohydrat, hypromellose, titandioxid (E171), 
glyceroltriacetat, FD&amp;C blå (E132), gul jernoxid (E172)), </p>
</li>
<li>
<p>Opadry klar (indeholder hypromellose, macrogol). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Mimpara er en lysegrøn, filmovertrukket tablet. Den er oval og har "30", "60" eller "90" markeret på 
den ene side og "AMG" på den anden side. </p>
<p>30 mg tabletter er cirka 9,7 mm lange og 6,0 mm brede. 
60 mg tabletter er cirka 12,2 mm lange og 7,6 mm brede. 
90 mg tabletter er cirka 13,9 mm lange og 8,7 mm brede. </p>
<p>Mimpara fås i blisterpakninger med 30 mg, 60 mg eller 90 mg filmovertrukne tabletter. Hver 
blisterpakning indeholder enten 14, 28 eller 84 tabletter i en æske. 
Mimpara fås i beholdere med 30 mg, 60 mg eller 90 mg filmovertrukne tabletter i en æske. Hver 
beholder indeholder 30 tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
Holland </p>
<p>Indehaver af markedsføringstilladelsen 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
Holland </p>
<p>Fremstiller 
Amgen NV 
Telecomlaan 5-7 
1831 Diegem 
Belgien </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
s.a. Amgen n.v. 
Tel/Tél: +32 (0)2 7752 
Lietuva 
Amgen Switzerland AG Vilniaus filialas 
Tel: +370 5 219 7България 
Амджен България ЕООД 
Тел.: +359 (0)2 424 7Luxembourg/Luxemburg 
s.a. Amgen 
Belgique/Belgien 
Tel/Tél: +32 (0)2 7752 
Česká republika 
Amgen s.r.o. 
Tel: +420 221 773 Magyarország 
Amgen Kft. 
Tel.: +36 1 35 44 Danmark 
Amgen, filial af Amgen AB, Sverige 
Tlf: +45 39617 
Malta 
Amgen B.V. 
The Netherlands 
Tel: +31 (0)76 5732 
Deutschland 
AMGEN GmbH 
Tel.: +49 89 1490 
Nederland 
Amgen B.V. 
Tel: +31 (0)76 5732 </p>
<p>Eesti 
Amgen Switzerland AG Vilniaus filialas 
Tel: +372 586 09Norge 
Amgen AB 
Tel: +47 23308 
Ελλάδα 
Amgen Ελλάς Φαρμακευτικά Ε.Π.Ε. 
Τηλ.: +30 210 3447 
Österreich 
Amgen GmbH 
Tel: +43 (0)1 50<br />
España 
Amgen S.A. 
Tel: +34 93 600 18<br />
Polska 
Amgen Biotechnologia Sp. z o.o. 
Tel.: +48 22 581 3France 
Amgen S.A.S. 
Tél: +33 (0)9 69 363 Portugal 
Amgen Biofarmacêutica, Lda. 
Tel: +351 21 4220 
Hrvatska 
Amgen d.o.o. 
Tel: +385 (0)1 562 57 România 
Amgen România SRL 
Tel: +4021 527 3 
Ireland 
Amgen Ireland Limited 
Tel: +353 1 8527 
Slovenija 
AMGEN zdravila d.o.o. 
Tel: +386 (0)1 585 1 
Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Amgen Slovakia s.r.o. 
Tel: +421 2 321 114<br />
Italia 
Amgen S.r.l. 
Tel: +39 02 6241Suomi/Finland 
Amgen AB, sivuliike Suomessa/Amgen AB, filial 
i Finland 
Puh/Tel: +358 (0)9 54900 
Kύπρος 
C.A. Papaellinas Ltd 
Τηλ.: +357 22741 Sverige 
Amgen AB 
Tel: +46 (0)8 6951 
Latvija 
Amgen Switzerland AG Rīgas filiāle 
Tel: +371 257 25 
United Kingdom (Northern Ireland) 
Amgen Limited 
Tel: +44 (0)1223 420 
Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om Mimpara på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Indlægsseddel: Information til patienten </p>
<p>Mimpara 1 mg granulat i kapsler til åbning 
Mimpara 2,5 mg granulat i kapsler til åbning 
Mimpara 5 mg granulat i kapsler til åbning 
cinacalcet </p>
<p>Læs denne indlægsseddel grundigt, inden De begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. De kan få brug for at læse den igen. 
- Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er mere, De vil vide. 
- Lægen har ordineret dette lægemiddel til Dem personligt. Lad derfor være med at give det til 
andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som De har. 
- Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis De får bivirkninger, herunder 
bivirkninger, som ikke er nævnt i denne indlægsseddel. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-168192a0c6d5270d5bcdb3cfa6cdd926
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for mimpara Package Leaflet for language en"
Description: "ePI document Bundle for mimpara Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-168192a0c6d5270d5bcdb3cfa6cdd926"
* entry[0].resource = composition-en-168192a0c6d5270d5bcdb3cfa6cdd926

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp168192a0c6d5270d5bcdb3cfa6cdd926"
* entry[=].resource = mp168192a0c6d5270d5bcdb3cfa6cdd926
                            
                    
Instance: bundlepackageleaflet-da-168192a0c6d5270d5bcdb3cfa6cdd926
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for mimpara Package Leaflet for language da"
Description: "ePI document Bundle for mimpara Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-168192a0c6d5270d5bcdb3cfa6cdd926"
* entry[0].resource = composition-da-168192a0c6d5270d5bcdb3cfa6cdd926

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp168192a0c6d5270d5bcdb3cfa6cdd926"
* entry[=].resource = mp168192a0c6d5270d5bcdb3cfa6cdd926
                            
                    



Instance: mp168192a0c6d5270d5bcdb3cfa6cdd926
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Mimpara 30 mg film-coated tablets"
Description: "Mimpara 30 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/04/292/001 – 30 mg carton with 14 tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Mimpara 30 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 168192a0c6d5270d5bcdb3cfa6cdd926ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "mimpara"

* status = #current
* mode = #working

* title = "List of all ePIs associated with mimpara"

* subject = Reference(mp168192a0c6d5270d5bcdb3cfa6cdd926)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#mimpara "mimpara"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-168192a0c6d5270d5bcdb3cfa6cdd926) // mimpara en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-168192a0c6d5270d5bcdb3cfa6cdd926) // mimpara da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-168192a0c6d5270d5bcdb3cfa6cdd926
InstanceOf: List

* insert 168192a0c6d5270d5bcdb3cfa6cdd926ListRuleset
    